Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis
Authors' conclusion
The use of PDE5i primarily in men with or without known coronary artery disease was associated with a lower risk for cardiovascular events and overall mortality.
Study context
- Population
- Mostly men (99.4%), median age 61.5 years, with or without known CAD
- Participants
- 1,257,759 men16 studies
- Comparison
- PDE5i vs other erectile dysfunction (ED) treatment, placebo or no treatment
- Outcome
- (1) major adverse cardiovascular events (MACE) and (2) all-cause mortality
- Follow-up
- Median 4.3 years
Pooled result
As reported in the abstract
PDE5i vs ControlRelative risk (95% CI)
MACE
0.78(0.69–0.89)
All-cause mortality (13 studies)
0.70(0.56–0.87)
Original publication
Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. Published 30 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →